Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | MicrobiomeTrials
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-02-22Est. Completion: 2029-06-02
Enrollment target: 48 participants
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Northwestern University, Chicago, Illinois, United States
Carle at The Riverfront, Danville, Illinois, United States
Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
Carle Physician Group-Effingham, Effingham, Illinois, United States
Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States
Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
Carle BroMenn Medical Center, Normal, Illinois, United States
Carle Cancer Institute Normal, Normal, Illinois, United States
Northwestern Medicine Oak Brook, Oak Brook, Illinois, United States
Other microbiome trials you might be interested in